To assess the impact of oral cannabidiol ( CBD) administration in addition to traditional antiepileptic remedy on seizure frequency in dogs with idiopathic epilepsy.


Randomized blinded controlled clinical trial.


26 client-owned dogs with intractable idiopathic epilepsy.


Dogs had been randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (two.five mg/kg [1.1 mg/lb], PO) twice every day for 12 weeks in addition to current antiepileptic therapies, and the placebo group received noninfused oil below the identical situations. Seizure activity, adverse effects, and plasma CBD concentrations had been compared amongst groups.


two dogs in the CBD group created ataxia and had been withdrawn from the study. Following other exclusions, 9 dogs in the CBD group and 7 in the placebo group had been integrated in the evaluation. Dogs in the CBD group had a considerable (median transform, 33%) reduction in seizure frequency, compared with the placebo group. Even so, the proportion of dogs deemed responders to remedy (≥ 50% lower in seizure activity) was equivalent amongst groups. Plasma CBD concentrations had been correlated with reduction in seizure frequency. Dogs in the CBD group had a considerable raise in serum alkaline phosphatase activity. No adverse behavioral effects had been reported by owners.


Even though a considerable reduction in seizure frequency was accomplished for dogs in the CBD group, the proportion of responders was equivalent amongst groups. Offered the correlation amongst plasma CBD concentration and seizure frequency, added investigation is warranted to identify no matter if a greater dosage of CBD would be productive in decreasing seizure activity by ≥ 50%.